Innovating Works
IMI2-2017-12-02
IMI2-2017-12-02: FAIRification of IMI and EFPIA data
Specific Challenge:Since 2008, numerous IMI consortia have been generating results in a diverse set of biomedical domains. In many projects these results have been stored in a custom database, sufficient for the project itself but difficult to access by scientists outside the project. The same is true for many internal industry research and development databases.
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 24-10-2017.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Specific Challenge:Since 2008, numerous IMI consortia have been generating results in a diverse set of biomedical domains. In many projects these results have been stored in a custom database, sufficient for the project itself but difficult to access by scientists outside the project. The same is true for many internal industry research and development databases.

Making a significant portion of the data from IMI projects accessible and interoperable with other datasets and databases will greatly improve the use and impact of the data for translational biomedical research.

The concept of FAIR data (Findable, Accessible, Interoperable, Reusable) is perfectly suited for this task


Scope:The project will focus on IMI projects that have data that is scientifically valuable and amenable to being made FAIR. It is expected that the databases of more than 20 IMI projects will be made FAIR in this project. All IMI projects will be assessed for the presence of such data that requires FAIRification, though it should be noted that IMI2 projects are already required to manage their data according to similar protocols.


Expected Impa... ver más

Specific Challenge:Since 2008, numerous IMI consortia have been generating results in a diverse set of biomedical domains. In many projects these results have been stored in a custom database, sufficient for the project itself but difficult to access by scientists outside the project. The same is true for many internal industry research and development databases.

Making a significant portion of the data from IMI projects accessible and interoperable with other datasets and databases will greatly improve the use and impact of the data for translational biomedical research.

The concept of FAIR data (Findable, Accessible, Interoperable, Reusable) is perfectly suited for this task


Scope:The project will focus on IMI projects that have data that is scientifically valuable and amenable to being made FAIR. It is expected that the databases of more than 20 IMI projects will be made FAIR in this project. All IMI projects will be assessed for the presence of such data that requires FAIRification, though it should be noted that IMI2 projects are already required to manage their data according to similar protocols.


Expected Impact: Allow the scientific community to maximally leverage data from legacy and current IMI projects. Strong increase of expertise in creation, curation, and stewardship of FAIR databases within IT communities. Building skills and increasing competiveness for SMEs in Europe. Allow the SME community to make their data, analysis tools and services better connected and aligned to pharma data and facilitate future collaboration. Interoperability of the databases will allow sophisticated data analysis in all phases of drug discovery, including advanced analytical methods such as computer reasoning and inferencing. The project will have a significant impact on the scientific community regarding the broad adaptation of FAIR data stewardship.
ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Specific Challenge:Since 2008, numerous IMI consortia have been generating results in a diverse set of biomedical domains. In many projects these results have been stored in a custom database, sufficient for the project itself but difficult to access by scientists outside the project. The same is true for many internal industry research and development databases. Specific Challenge:Since 2008, numerous IMI consortia have been generating results in a diverse set of biomedical domains. In many projects these results have been stored in a custom database, sufficient for the project itself but difficult to access by scientists outside the project. The same is true for many internal industry research and development databases.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Amortizaciones.
Activos.
Otros Gastos.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Please read carefully all provisions below before the preparation of your application.
The IMI2 12th Call for proposals topic text as well as the Call Conditions are available here
1. List of countries and applicable rules for funding: described in article 10(2) of Regulation N° 1290/2013 of 11 December 2013 laying down the rules for participation and dissemination in Horizon 2020 and in article 1 of the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014.
2. Eligibility and admissibility conditions: described in the IMI2 Manual for evaluation, submission and grant award See also the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014.
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
3. Evaluation
Submission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the IMI2 Manual for submission, evaluation and grant award. See also the proposal templates for your specific action in section 5, below.
4. Indicative timetable for evaluation and grant agreement:
Notification of outcomes of stage 1 evaluations: Maximum 5 months from deadline for submitting proposals.
Notification of outcomes of stage 2 evaluations: Maximum 5 months from deadline for submitting full proposals.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants. Please read carefully all provisions below before the preparation of your application.
The IMI2 12th Call for proposals topic text as well as the Call Conditions are available here
1. List of countries and applicable rules for funding: described in article 10(2) of Regulation N° 1290/2013 of 11 December 2013 laying down the rules for participation and dissemination in Horizon 2020 and in article 1 of the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014.
2. Eligibility and admissibility conditions: described in the IMI2 Manual for evaluation, submission and grant award See also the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014.
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
3. Evaluation
Submission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the IMI2 Manual for submission, evaluation and grant award. See also the proposal templates for your specific action in section 5, below.
4. Indicative timetable for evaluation and grant agreement:
Notification of outcomes of stage 1 evaluations: Maximum 5 months from deadline for submitting proposals.
Notification of outcomes of stage 2 evaluations: Maximum 5 months from deadline for submitting full proposals.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
5. Provisions, proposal templates and evaluation forms:
IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):
Proposal templates are available after entering the submission tool
Standard evaluation form 
IMI2 Model Grant Agreement
Clinical trial template – the Clinical Trial template is compulsory at stage 2 only !
6. Additional provisions:
Open access must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged. Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
This topic participates per default in the open access to research data pilot which aims to improve and maximise access to and re-use of research data generated by projects:
- The pilot applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available for open access and need to describe their approach in a Data Management Plan (to be provided within six months after the project start).
- Note that the evaluation phase proposals will not be evaluated more favourably because they are part of the Pilot, and will not be penalised for opting out of the Pilot.
- Projects can at any stage opt-out of the pilot.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
Further information on the Open Research Data Pilot is made available in the H2020 Online Manual: http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/open-access-dissemination_en.htm 
7. Additional documents:
Summary of the most relevant provisions for participating in IMI2 actions
IMI2 Annual Work Plan 2017 
IMI2 Regulators Guidance tool for researchers 
IMI JU derogation to H2020 Rules for Participation  
Horizon 2020 Rules for Participation 
Horizon 2020 Regulation of Establishment
Horizon 2020 Specific Programme 
 
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-JTI-IMI2-2017-12-two-stage FAIRification of IMI and EFPIA data Specific Challenge:Since 2008, numerous IMI consortia have been generating results in a diverse set of biomedical domains. In many projects...
Sin info.
IMI2-2017-12-05 European Health Data Network (EHDN)
en consorcio:
Cerrada hace 2 años | Próxima convocatoria prevista para el mes de
IMI2-2017-13-10 Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
en consorcio: Specific Challenge:Neurotoxicity (used in the context of this document as “any adverse effect on the central nervous system (CNS) or periphe...
Cerrada hace 7 años | Próxima convocatoria prevista para el mes de
IMI2-2017-13-02 Genome-Environment Interactions in Inflammatory Skin Disease
en consorcio: Specific Challenge:Inflammatory skin diseases affect a significant percentage of our global population. Atopic Dermatitis (AD) affects appro...
Cerrada hace 7 años | Próxima convocatoria prevista para el mes de
IMI2-2017-13-08 Human Tumour Microenvironment Immunoprofiling
en consorcio: Specific Challenge:To improve therapy, the understanding of the tumour microenvironment needs to evolve. Firstly, the understanding of tumou...
Cerrada hace 7 años | Próxima convocatoria prevista para el mes de
IMI2-2017-13-14 Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases
en consorcio: Specific Challenge:On average it takes about 14 years for a new drug to travel from the research lab to market approval at an average cost o...
Cerrada hace 7 años | Próxima convocatoria prevista para el mes de